1. Home
  2. NREF vs SABS Comparison

NREF vs SABS Comparison

Compare NREF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

HOLD

Current Price

$16.85

Market Cap

296.5M

Sector

Real Estate

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.51

Market Cap

280.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NREF
SABS
Founded
2019
2014
Country
United States
United States
Employees
N/A
86
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.5M
280.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NREF
SABS
Price
$16.85
$3.51
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$14.00
$10.75
AVG Volume (30 Days)
62.7K
914.7K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
13.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.47
N/A
P/E Ratio
$4.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.36
$1.85
52 Week High
$17.22
$5.15

Technical Indicators

Market Signals
Indicator
NREF
SABS
Relative Strength Index (RSI) 65.87 40.95
Support Level $13.73 $3.42
Resistance Level N/A $4.10
Average True Range (ATR) 0.36 0.20
MACD 0.11 -0.04
Stochastic Oscillator 77.03 8.33

Price Performance

Historical Comparison
NREF
SABS

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: